“Incidence and Factors Associated With Adverse Drug Reactions in a Cohort of Individuals Starting Dolutegravir or Efavirenz ”. Research, Society and Development, vol. 11, no. 4, Mar. 2022, p. e0811426250, https://doi.org/10.33448/rsd-v11i4.26250.